SecBot SecBot
8-K ·Filed Aug 31, 2026

CERO

CERO THERAPEUTICS HOLDINGS, INC.
BEARISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001213900-26-095776
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

This is a distressed bridge loan with a 7-week maturity, the company must either repay, refinance, or face default by mid-October. The secured position of SRX (first lien on all subsidiary IP and stock) means unsecured creditors and equity holders are structurally subordinated. Monitor for any subsequent financing, restructuring, or going-concern disclosure before the October 15 maturity date. The elimination of conversion features from the prior notes removes a potential equity-linked upside for noteholders, increasing the likelihood of a distressed outcome.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$0.0120
T+0 close · Aug 31, 2026 · via day close
Latest settled
−12.50%
T+20 · $0.0105 · next T+60 in 8d
Vs SPY
−13.68%
α at T+20
Latest observation
−35.76%
T+53 · FF3 residual α
  1. T+0 · Sep 1 $0.0120entry
  2. T+1 · 3mo ago +31.67%α +31.22% · $0.0158
  3. T+5 · 2mo ago −8.33%α −8.41% · $0.0110
  4. T+20 · 7w ago −12.50%α −13.68% · $0.0105
  5. T+53 · todayOpen
  6. T+60 · in 8d Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CERO Therapeutics completed a secured financing with SRX Global, consolidating $5.67M of prior unsecured debt into a new senior secured promissory note and securing up to $6M in additional advances (total facility up to $11.67M). The company received an initial $775,665 advance (net $725,665 after legal fees) for working capital. The note matures October 15, 2026, bears 10% interest (24.99% default rate), and is secured by a pledge of 100% of the subsidiary's stock and substantially all subsidiary assets including key IP for CER-1236. The subsidiary also provided an unconditional guaranty. This is a distressed financing with a very short maturity, signaling acute liquidity needs and high refinancing risk.

Key Financial Metrics

Deal Value
$11.7M
Deal Type
credit_facility
Offering Size
$11.7M

Key Facts

  • Consolidated $5,666,108.77 of prior unsecured debt into a single senior secured note with SRX Global.
  • New facility provides up to $6,000,000 in additional advances, with an initial $775,665 advance funded on August 27, 2026.
  • Maturity date is October 15, 2026, only ~7 weeks from the filing date, with SRX holding unilateral extension rights for up to four 30-day periods.
  • Interest rate is 10% per annum, escalating to 24.99% upon an Event of Default.
  • Collateral includes 100% of the subsidiary's stock (via Pledge Agreement) and substantially all subsidiary assets including key CER-1236 patents and IP (via Asset Security Agreement).
  • The subsidiary (CERo Therapeutics, Inc.) provided an absolute, unconditional guaranty of payment.
  • Proceeds are for paying outstanding trade payables and working capital, no growth or pipeline funding.
  • The company cannot prepay the note without SRX's consent except in a change-of-control transaction.
  • Previous convertible notes (from Keystone Capital Partners and SRX) were terminated and replaced, eliminating conversion features.

Financial Impact

Up to $11.67M in total secured debt, with $5.67M already outstanding and $775,665 new cash (net $725,665). Very short maturity (Oct 15, 2026) creates acute refinancing risk.

debtliquiditydilution

Risk Factors

  • Inability to repay or refinance the $5.67M+ by October 15, 2026, triggering default and potential loss of all subsidiary assets to SRX.
  • Very short maturity (7 weeks) with no committed refinancing, extreme liquidity risk.
  • Secured position of SRX over all key IP (CER-1236 patents) means equity holders could be wiped out in a default scenario.
  • Negative covenants restrict additional indebtedness and liens, limiting financing alternatives.
  • The company is trading on OTC with no analyst coverage and 0% bullish consensus, limited access to capital markets.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
0% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-095776
Document: ea030403701ex10-2.htm0001213900-26-095776
Document: ea030403701ex10-3.htm0001213900-26-095776
Document: ea0304037-8k_cero.htm0001213900-26-095776
Document: ea030403701ex10-4.htm0001213900-26-095776
Document: 0001213900-26-095776-index-headers.html0001213900-26-095776
Document: 0001213900-26-095776-index.html0001213900-26-095776
Document: 0001213900-26-095776.txt0001213900-26-095776

Track record

5 reports on CERO

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +65.71% at T+60 after the Mar 11, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Oct 7, 20265w ago 8-K Bearish 6/10 Entry $0.0951 Now $0.005000 +94.74% No price data
  2. Aug 31, 202611w ago 8-K Bearish 7/10 Viewing Entry $0.0120 to $0.0105 Now $0.005000 +58.33% ▲ +12.50% +13.68% vs SPY
  3. Jul 13, 202618w ago 25-NSE Bearish 7/10 Entry $0.0150 to $0.0100 Now $0.005000 +66.67% ▲ +33.33% +36.52% vs SPY
  4. Jun 26, 202620w ago 8-K Bearish 6/10 Entry $0.0110 to $0.009700 Now $0.005000 +54.55% ▲ +11.82% +11.56% vs SPY
  5. Mar 11, 202635w ago 8-K Bearish 7/10 Entry $0.0350 to $0.0340 Now $0.005000 +85.71% ▲ +2.86% +3.38% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 7h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 31, 2026